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Introduction: Docetaxel and erlotinib are registered second-
line treatments for wild-type EGFR NSCLC. Previous studies
suggested a predictive value of the VeriStrat test in second-
line therapy of NSCLC, classifying patients as either VeriStrat
good or VeriStrat poor. EMPHASIS-lung aimed at exploring
this predictive effect in patients with squamous cell NSCLC.
The trial closed prematurely because of low accrual and re-
sults from other trials. Our analysis includes an exploratory
combined analysis with results from the PROSE trial.
Methods: EMPHASIS-lung was a randomized phase III
multicenter trial exploring the differential effect of second-
line erlotinib versus docetaxel on progression-free survival
(PFS) in VeriStrat good versus VeriStrat poor patients with
squamous cell NSCLC.
Results: A total of 80 patients were randomized, with
72.5% categorized as VeriStrat good. Patient characteristics
were balanced between VeriStrat status and treatment
groups. The median PFS times with docetaxel and erlotinib
treatment in the VeriStrat good cohort were 4.1 and 1.6
months, respectively, versus 1.9 and 2.1 months, respec-
tively, in the VeriStrat poor cohort. The median overall
survival (OS) times with docetaxel and erlotinib treatment
in the VeriStrat good cohort were 7.8 and 8.4 months,
respectively, and 4.4 and 5.2 months, respectively, in the
VeriStrat poor cohort. An additional exploratory analysis
was performed; in it, 47 patients from the squamous cell
subgroup of PROSE were included in a combined analysis,
contributing with 45 PFS and 41 OS events.Conclusions: The final analysis of EMPHASIS-lung did not
showadifferential effect onPFS for erlotinib versusdocetaxel
stratified by VeriStrat status. Similarly, in the combined
analysis, no significant treatment by VeriStrat status inter-
actionwasobserved (interactionp¼0.24 for PFS and0.45 for
OS, stratified by study).
 2017 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. All rights reserved.
Keywords: NSCLC; Squamous; Erlotinib; Docetaxel; ETOP;
VeriStrat
Introduction
NSCLC accounts for 80% to 85% of lung cancers. The
prevalence of the squamous cell histological subtype
accounts for 25% to 30% of NSCLC.1,2 Although the
molecular characterization of lung tumors has revolu-
tionized the treatment strategies for oncogene-addicted
nonsquamous cell NSCLC, an unmet need exists for
effective treatment of patients with squamous cell
NSCLC, especially in the second- and third-line settings.
Single-agent chemotherapy can improve disease-
related symptoms and survival.3–5 Docetaxel and erloti-
nib are comparable and registered as second-line
treatment options for squamous cell NSCLC. Erlotinib
was shown to improve overall survival (OS) as second-
line or third-line therapy in unselected NSCLC, whereas
gefitinib and docetaxel demonstrated equivalent activity
in terms of progression-free survival (PFS) and OS.3,6
754 Peters et al Journal of Thoracic Oncology Vol. 12 No. 4In refractory patients, erlotinib was shown to be
equivalent to docetaxel and both compounds demon-
strated equivalence in patientswithEGFRwild-type NSCLC
with respect to OS, with modest improvement of PFS for
docetaxel.7,8 This is in good agreementwith thefindings for
erlotinib as second- or third-line therapy, inwhich superior
PFS but not OS for docetaxel was demonstrated.9 In
advanced-stage squamous cell NSCLC progressing
after chemotherapy, afatinib demonstrated a modest
benefit in terms of PFS and OS compared with erlotinib.10
Recently, the programmed cell death 1–targeting
immune checkpoints inhibitors nivolumab and pem-
brolizumab have been shown to result in prolonged OS
as compared with docetaxel in the second- or third-line
setting,11,12 and where available, these agents are more
and more replacing docetaxel or erlotinib as second-line
therapies.
The clinically validated serum proteomic test VeriStrat
(Biodesix, Boulder, CO) is used to classify patients as
either VeriStrat good or VeriStrat poor by using the in-
tensity of eight mass-to-charge ratio features in the mass
spectra obtained from pretreatment serum samples.13
Retrospective studies showed that VeriStrat good pa-
tients have significantly better outcomes than VeriStrat
poor patients when treated with EGFR tyrosine kinase
inhibitors (TKIs).14–18 In the randomized phase III study
PROSE, 285patientswith stage IIIB or IVNSCLC afterfirst-
line therapy were randomly assigned to either chemo-
therapy or erlotinib. Patients were stratified on the basis
of VeriStrat status.19 A significant interaction between
treatment and proteomic classification was documented
in this trial, with VeriStrat poor patients having worse OS
when receiving erlotinib than when receiving chemo-
therapy,whereas for VeriStrat good patients no significant
difference in OS between treatments was detected.
The EMPHASIS-lung trial aimed to explore the pre-
dictive value of VeriStrat with respect to PFS in patients
with squamous cell NSCLC treated with erlotinib versus
treated with docetaxel. The trial was closed prematurely
on account of low accrual and release of the results from
the PROSE and TAILOR trials.20
Here we present the final results regarding PFS and
OS for the EMPHASIS-lung trial as well as for an
exploratory combined analysis that included the squa-
mous cell NSCLC cohort of the PROSE trial.Methods
Study Design, Key Eligibility Criteria, and Trial
Treatment
This clinical trial was a randomized, open label phase
III trial exploring the differential effect of erlotinib
versus docetaxel on PFS in VeriStrat good versus Veri-
Strat poor patients.The eligibility criteria comprised stage IIIB squamous
cell NSCLC not amenable to radical radiotherapy or
metastatic stage IV disease (according to the seventh
TNM classification); documented progressive disease
during or after a previous line of chemotherapy
(including platinum-doublet therapy); an Eastern Coop-
erative Oncology Group performance status of 0 to 2; and
adequate hematological, hepatic, and renal function. Pa-
tients with activating EGFR mutation and patients previ-
ously exposed to EGFR TKIs or docetaxel were excluded.
Written informed consent was obtained from all patients.
Patients were randomized 1:1 to receive either erlo-
tinib, 150 mg/d orally, or docetaxel, 75 mg/m2 intrave-
nously, on day 1 of every 21-day cycle. Serum samples
were collected from each patient for further VeriStrat
testing in the central laboratory at Biodesix. The inves-
tigative sites and personnel were blinded to the result of
the VeriStrat test, which was used only for randomiza-
tion. Tumor response or disease progression was
assessed with thorax-abdomen computed tomography
scans at 6-week intervals according to the Response
Evaluation Criteria in Solid Tumors.
Block-stratified randomization balanced by center
using a minimization algorithm21 was used, with the
stratification factors VeriStrat status (VeriStrat good
versus VeriStrat poor) and performance status (0–1
versus 2). The protocol was approved by institutional
review boards at each site, and the trial was conducted
in accordance with the Declaration of Helsinki, the
Guideline for Good Clinical Practice, and the Interna-
tional Conference on Harmonization Tripartite Guideline.
Safety was reviewed by the European Thoracic Oncology
Platform independent data monitoring committee.
Statistical Analysis
The primary end point was PFS, defined as the time
from randomization until documented progression or
death if occurring without documented progression for
all randomized patients (the intent-to-treat population).
The statistical design was based on an expected
hazard ratio (HR) of erlotinib versus docetaxel of 0.675
for the VeriStrat good patients (median PFS of 4.0
months with erlotinib and 2.7 months with docetaxel),
and 1.23 for the VeriStrat poor patients (median PFS of
2.2 months with erlotinib and 2.7 months with doce-
taxel). A sample size of 500 was needed to achieve 86%
power for testing the expected interaction HR of 1.82 at
the 0.05 two-sided significance level.
Baseline characteristics were compared between
treatments and VeriStrat groups by Fisher’s exact test
(categorical variables) and the Mann-Whitney test
(continuous variables). The log-rank test was used to
detect differences in PFS and OS between the treatment
arms within each VeriStrat population (Veristrat
April 2017 EMPHASIS-lung: Predictive Value of VeriStrat 755stratified log-rank was used in the total population). The
impact of treatment and VeriStrat status and their
interaction on PFS and OS was explored through
appropriate Cox proportional hazards models adjusted
for variables of clinical interest (sex, age, performance
status, and smoking status).
A stochastic curtailment approach was applied to es-
timate the conditional power at the end of the study if it
were to be continued to completion. In addition, a com-
bined analysis of the EMPHASIS-lung data with data for
the squamous cell cohort of the PROSE trial was included.
All analyses were performed with the SAS 9.3 statis-
tical package (SAS Institute Inc., Cary, NC), and R software
(R Foundation for Statistical Computing, Vienna, Austria)
was used for the stochastic curtailment simulations.PROSE Squamous Cell Cohort
The primary end point in the PROSE trial was OS, with
PFS as a secondary end point. Patients were randomized
to receive either erlotinib (150 mg orally daily) or
chemotherapy (up to six cycles of docetaxel, 75 mg/m2
intravenously) and stratified by VeriStrat status, perfor-
mance status, smoking, and center. Tumor response or
disease progression was assessed with thorax-abdomenFigure 1. CONSORT diagram of the EMPHASIS trial. pt, patien
follow-up.computed tomography scans at 8-week intervals accord-
ing to the Response Evaluation Criteria in Solid Tumors.
The squamous cell cohort of the PROSE trial population
was used as a subgroup in the combined analysis.
Combined EMPHASIS-lung and PROSE Squamous
Cell Cohort Analysis
The evaluation of the combined cohort (EMPHASIS-
lung patients and squamous cell cohort of the PROSE
trial) was stratified by trial, with OS as the primary ef-
ficacy measure. The baseline characteristics were
compared and the data were combined through the
appropriate multivariate Cox proportional hazards
model for OS, with variables of clinical interest and the
data source used as possible covariates.
Results
Study Cohorts
Two trial cohorts were analyzed: the EMPHASIS-lung
cohort of 80 patients randomized from January 2013 and
January 2014 (CONSORT diagram in Fig. 1) and the
PROSE cohort comprising 47 patients with the squamous
cell histological subtype (randomized from 2008–2012).
A combined data set was used for outcome evaluation.t; ITT, intent-to-treat; PFS; progression-free survival; f-up,
Table 1. Patient Baseline Characteristics
EMPHASIS-lung Cohort PROSE Cohort
Treatment Arm VeriStrat Status
All
Patients
(N ¼ 80)
VeriStrat Status
Erlotinib
(n ¼ 38)
Docetaxel
(n ¼ 42)
p
Value
VeriStrat
Good
(n ¼ 58)
VeriStrat
Poor
(n ¼ 22)
p
Value
VeriStrat
Good
(n ¼ 29)
VeriStrat
Poor
(n ¼ 18)
p
Value
All
Patients
(N ¼ 47)
Categorical Characteristics Categorical Characteristics
Sex, n (%)
Male 31 (81.6) 35 (83.3) >0.99a 46 (79.3) 20 (90.9) 0.33 66 (82.5) 21 (72.4) 17 (94.4) 0.12a 38 (80.9)
Female 7 (18.4) 7 (16.7) 12 (20.7) 2 (9.1) 14 (17.5) 8 (27.6) 1 (5.6) 9 (19.1)
Smoking history, n (%)
Current 16 (42.1) 12 (28.6) 0.41a 22 (37.9) 6 (27.3) 0.76a 28 (35.0) 6 (20.7) 11 (61.1) 0.013a 17 (36.2)
Former (>100 cigs and
>12 mo smoke-free)
20 (52.6) 28 (66.7) 33 (56.9) 15 (68.2) 48 (60.0) 21 (72.4) 7 (38.9) 28 (59.6)
Never 2 (5.3) 2 (4.8) 3 (5.2) 1 (4.5) 4 (5.0) 2 (6.9) 0 (0.0) 2 (4.3)
ECOG performance status, n (%)
0 12 (31.6) 15 (35.7) 0.52a 16 (27.6) 11 (50.0) 0.12a 27 (33.8) 19 (65.5) 7 (38.9) 0.17a 26 (55.3)
1 24 (63.2) 22 (52.4) 37 (63.8) 9 (40.9) 46 (57.5) 8 (27.6) 9 (50.0) 17 (36.2)
2 2 (5.3) 5 (11.9) 5 (8.6) 2 (9.1) 7 (8.8) 2 (6.9) 2 (11.1) 4 (8.5)
VeriStrat status, n (%)
Good 28 (73.7) 30 (71.4) >0.99a 58 (72.5)
Poor 10 (26.3) 12 (28.6) 22 (27.5)
Continuous characteristic Continuous characteristic
Age, y
Mean (95% CI) 66.3
(63.5–
69.2)
69.7
(67.3–
72.1)
0.065b 69.3
(67.4–
71.3)
64.9
(60.4–
69.3)
0.11b 68.1
(66.3–
70.0)
68.1
(65.2–
70.9)
69.1
(65.0–
73.2)
0.51b 68.5
(66.2–
70.7)
Median (Min-Max) 66.7
(44.4–
81.9)
70.1
(53.3–
84.0)
69
(56.1–
84.0)
65.3
(44.4–
81.9)
68.7
(44.4–
84.0)
67
(50.0–
84.0)
68
(53.0–
84.0)
68
(50.0–
84.0)
aFisher’s exact test.
bMann-Whitney test.
cig, cigarette; ECOG, Eastern Cooperative Oncology Group; CI, confidence interval; Min-Max, minimum-maximum.
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Table 2. Patient baseline characteristics by treatment and VeriStrat group for the EMPHASIS-lung Cohort
VeriStrat Good (n ¼ 58) VeriStrat Poor (n ¼ 22)
Treatment Arm Treatment Arm
Erlotinib
(n ¼ 28)
Docetaxel
(n ¼ 30)
p
Value
Erlotinib
(n ¼ 10)
Docetaxel
(n ¼ 12)
p
Value
Categorical Characteristics Categorical Characteristics
Sex, n (%)
Male 22 (78.6) 24 (80.0) >0.99a 9 (90.0) 11 (91.7) >0.99a
Female 6 (21.4) 6 (20.0) 1 (10.0) 1 (8.3)
Smoking history, n (%)
Current 12 (42.9) 10 (33.3) 0.55a 4 (40.0) 2 (16.7) 0.35a
Former (>100 cigs and
>12 mo smoke-free)
14 (50.0) 19 (63.3) 6 (60.0) 9 (75.0)
Never 2 (7.1) 1 (3.3) 0 (0.0) 1 (8.3)
ECOG performance status, n (%)
0 7 (25.0) 9 (30.0) 0.85a 5 (50.0) 6 (50.0) 0.57a
1 19 (67.9) 18 (60.0) 5 (50.0) 4 (33.3)
2 2 (7.1) 3 (10.0) 0 (0.0) 2 (16.7)
Continuous characteristic Continuous characteristic
Age, y
Mean (95% CI) 68.1
(65.4–70.7)
70.5
(67.7–73.3)
0.18b 61.4
(53.1–69.7)
67.8
(62.8–72.8)
0.14b
Median (Min-Max) 67.1
(58.3–81.8)
70.1
(56.1–84.0)
60.1
(44.4–81.9)
69.8
(53.3–77.5)
aFisher’s exact test.
bMann-Whitney test.
cig, cigarette; ECOG, Eastern Cooperative Oncology Group; CI, confidence interval; Min-Max, minimum-maximum.
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EMPHASIS-lung Cohort. The baseline characteristics
are summarized in Table 1. Median age was 68.7 years,
with most patients being male (82.5%), being former or
current smokers (95.0%), and having good performance
status (91.3% with a performance status of 1). Patient
characteristics for the different treatment arms and
VeriStrat groups were similar (Tables 1 and 2).
The overall proportion of VeriStrat good patients was
72.5% (exact binomial 95% confidence interval [CI]:
61.4–81.9), which was higher than the anticipated 50%
used for the study design.
Combined EMPHASIS-lung and PROSE squamous cell
cohort. The distribution of baseline characteristics in
the PROSE cohort (see Table 1) with respect to VeriStrat
status was well balanced between treatment arms
except for smoking history (among current smokers, six
patients (20.7%) were classified as VeriStrat good and
11 patients (61.1%) were classified as VeriStrat poor
[p ¼ 0.013]).
The distribution of the patient characteristics was
similar in the two trials. This justified addressing the
main question regarding a predictive value of VeriStrat
in the combined cohort.Outcome
EMPHASIS-lung cohort. As of the data cutoff date of 31
December 2015, at a median follow-up time of 20.5
months (interquartile range 13.7–23.8 months), all pa-
tients had stopped trial treatment (median time on
treatment 2.1 months, interquartile range 1.2–4.3
months). Seventy-three patients had experienced a PFS
event (median PFS 2.7 months, 95% CI: 1.6–3.8) and 60
patients had died (median OS 7.1 months, 95% CI: 6.0–
8.6). Seven patients were lost to follow-up before expe-
riencing a PFS event.
PFS showed no difference by treatment (themedian PFS
times for erlotinib versus docetaxel were 1.6 versus 3.0
months stratified by VeriStrat status [p ¼ 0.32]). In the
VeriStrat good cohort, 51 patients (87.9%) experienced a
progression-defining event (the median PFS times for
erlotinib versus docetaxel were 1.6 versus 4.1 months [p¼
0.37]), whereas all 22 patients (100%) in the VeriStrat poor
group experienced a PFS event (the median PFS times for
erlotinib versus docetaxel were 2.1 versus 1.9 months [p¼
0.66]). No significantly different PFSwas found by VeriStrat
status or by any other variable of clinical interest in uni-
variate or multivariate model analyses. In the primary
analysis for PFS, no significant interaction between treat-
ment and VeriStrat status was found (p ¼ 0.80) (Fig. 2A).
Figure 2. Kaplan-Meier survival curves for progression-free survival (PFS) and overall survival (OS) in the EMPHASIS-lung
cohort (N ¼ 80). (A) PFS by treatment arm and VeriStrat status. (B) OS by VeriStrat status. (C) OS by treatment arm and
VeriStrat status. E-Good, VeriStrat good patients in the erlotinib arm; E-Poor, VeriStrat poor patients in the erlotinib arm;
D-Good, VeriStrat good patients in the docetaxel arm; D-Poor, VeriStrat poor patients in the docetaxel arm.
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Figure 2. (continued).
April 2017 EMPHASIS-lung: Predictive Value of VeriStrat 759The difference in OS between the two treatment arms
was not significant either overall (median OS was 7.1
months for both erlotinib and docetaxel stratified by
VeriStrat status [p ¼ 0.91]) or within each VeriStrat
group (OS of 8.4 versus 7.8 months for erlotinib versus
for docetaxel in patients with VeriStrat good status [p ¼
0.88] as opposed to 5.2 versus 4.4 months in patients
with VeriStrat poor status [p ¼ 0.68]), but the difference
was significant by VeriStrat status (p ¼ 0.012). In the
VeriStrat good population, 69.0% of patients died (40
deaths) with a median OS of 8.2 months (95% CI: 6.7–
10.6), whereas in the VeriStrat poor group the corre-
sponding proportion was 90.9% (20 deaths) with a
median OS of 5.2 months (95% CI: 3.1–7.1). VeriStrat
good patients experienced a statistically significant
reduced risk for death compared with VeriStrat poor
patients irrespective of the treatment (HR for Veristrat
good versus Veristrat poor status ¼ 0.50, 95% CI 0.29–
0.86) (Fig. 2B). This also applied when adjustment was
made for clinical variables of interest (model adjusted
for sex: HR for Veristrat good versus Veristrat poor
status ¼ 0.53, 95% CI: 0.30–0.92, p ¼ 0.023). The
interaction of treatment arm and VeriStrat status wasnot found to be significant either for OS or for PFS
(interaction p ¼ 0.72) (Fig. 2C).
Combined EMPHASIS-lung and PROSE squamous cell
cohort. No significant treatment by VeriStrat interaction
was observed for the combined cohort (p ¼ 0.24 and
0.45 for PFS/OS). Overall, 79.5% deaths with a median
OS of 7.2 months was observed. No significant difference
for OS could be observed either between the treatment
arms overall (median OS with erlotinib versus with
docetaxel, 7.0 versus 7.8 months [stratified p ¼ 0.13]) or
within each VeriStrat group separately (p ¼ 0.52 for
Veristrat good versus p ¼ 0.097 for VeriStrat poor). A
statistically significant difference in OS was observed
between the VeriStrat groups (p < 0.001), with 73.6%
deaths (median OS of 9.0 months) in the VeriStrat good
population versus 92.5% (median OS of 4.6 months)
in the VeriStrat poor population. The treatment and
VeriStrat HRs for PFS/OS in the individual and combined
cohorts are presented in Figure 3. No variable of clinical
interest had a significant effect either on PFS or on
OS. Results are estimated from the Cox models stratified
by study.
Figure 3. Forest plot of the effect of treatment and VeriStrat status (VS) on progression-free survival (PFS) and overall
survival (OS) shown individually for each trial (EMPHASIS-lung and PROSE) and for the combined cohort. E, erlotinib; D,
docetaxel; HR, hazard ratio; CI, confidence interval; PROSE-sq, squamous cell cohort from the PROSE trial; VSG, VeriStrat
good; VSP, VeriStrat poor.
760 Peters et al Journal of Thoracic Oncology Vol. 12 No. 4For the combined cohort, the impact of VeriStrat
status was found to be significant for both PFS and OS
(p ¼ 0.015 and p < 0.001, respectively), whereas
treatment was significant only for PFS (p ¼ 0.017).AEs
EMPHASIS-lung cohort. A total of 75 patients experi-
enced at least one adverse event (AE) (36 and 39 in each
treatment arm, respectively), whereas 26 patients had at
least one serious AE (SAE), from a total of 35 reported
SAEs. No unexpected SAE was observed. Ten fatal AEs
were recorded, with seven deaths during erlotinib
treatment and three during docetaxel treatment, all of
which were unrelated or unlikely to be related to trial
treatment.
Combined EMPHASIS-lung and PROSE Squamous Cell
Cohort. The AEs for the PROSE cohort have been re-
ported previously.19 They were similar to those reported
for the EMPHASIS-lung patients.
Discussion
In a series of clinical trials docetaxel was compared
with erlotinib as standard second-line chemotherapy for
unselected NSCLC, but no clear difference in antitumor
activity could be demonstrated.4,5,7–9 From a meta-
analysis it can be concluded that treatment with a
first-generation EGFR TKI compared with conventional
chemotherapy was associated with improvement in PFS
but not OS.22 This is also reflected in the current
guidelines,23 which leave both options up to the treating
oncologist’s decision. Hence, the choice between doce-
taxel and an EGFR TKI is made on the basis of subjective
arguments rather than scientific evidence in the face of
the obstacle that only few patients will ever receivesubsequent third-line therapy. This is especially true for
advanced NSCLC of the squamous cell histological sub-
type, which is characterized by short OS,24,25 and sup-
porting data would help in deciding on a strategy in the
second-line scenario for these patients.
In 2014, the PROSE trial showed a predictive ability
of the VeriStrat classification to differentiate treatment
benefits of chemotherapy versus erlotinib in the second-
line treatment of unselected advanced NSCLC,14 with a
significant interaction between treatment and test
classification with respect to OS. In particular, 30% of
VeriStrat poor patients demonstrated poor OS when
treated with erlotinib, whereas no treatment superiority
was found within the population of VeriStrat good pa-
tients. These results, together with the presentation of
the TAILOR trial9 and a related meta-analysis,22 did call
into question the role of erlotinib in the second-line
setting and hence also the aim of the EMPHASIS-lung
trial.
The final analysis of EMPHASIS-lung did not show a
differential effect of erlotinib versus docetaxel on PFS by
VeriStrat status in patients with NSCLC of the squamous
cell histological subtype, as is also clearly shown by the
significant overlap in the HR CIs (see Fig. 3). These re-
sults are at variance with previous studies, the PROSE
trial, and our trial assumptions. A plausible explanation
is the lack of power in the EMPHASIS-lung trial owing to
its early termination and low accrual. Indeed, conditional
power calculations indicated that if the trial had pro-
ceeded to completion, the power of detecting a treat-
ment by VeriStrat status interaction would still be
greater than 60%.
In the EMPHASIS-lung analysis, it was confirmed that
VeriStrat good patients had better OS than VeriStrat poor
patients, but no treatment effect either on PFS or on OS
was detected.
April 2017 EMPHASIS-lung: Predictive Value of VeriStrat 761In the combined analysis of the EMPHASIS-lung
patients and the squamous cell NSCLC cohort of the
PROSE trial, treatment with erlotinib was associated
with a significantly higher risk for progression and a
numerical but not significantly higher risk for death
compared with docetaxel for both VeriStrat good and
VeriStrat poor patients, and importantly, VeriStrat good
patients demonstrated a significantly lower risk for
progression and death compared with VeriStrat poor
patients.
In summary, although the prognostic ability of Veri-
Strat status could be confirmed, neither the EMPHASIS-
lung results nor the combined EMPHASIS-lung and
PROSE analysis results could show a predictive value of
the VeriStrat test with respect to a differential effect of
erlotinib versus docetaxel on the basis of the VeriStrat
classification for advanced squamous cell NSCLC.
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